Clarivate Plc

Clarivate Plc engages in the provision of global information, analytics and workflow solutions. It operates through the Science and Intellectual Property segments. The Science segment is composed of the academia and government, and life science and healthcare product lines. The Intellectual Property segment includes the patent, trademark, domain, and IP management product lines. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Clarivate Plc reports strong Q4 earnings, eyes growth opportunities

Clarivate Plc delivered strong financial results in Q4 2022, driven by the successful ProQuest acquisition and solid organic growth across segments. The company is focused on achieving higher organic growth, reducing leverage, and leveraging culture for success.
While facing macroeconomic challenges and pricing pressures, Clarivate Plc is confident in its strategic plans and capital structure initiatives. Opportunities lie in leveraging AI, enhancing product offerings, and capitalizing on the positive pricing environment.
Navigating challenges such as tough comps, managing inflation impact, and balancing quarterly patterns will be crucial. The company's proactive approach to growth, focus on customer value, and upcoming Investor Day position it well for future success.

Clarivate Plc reports stable Q1 performance amidst growth challenges

Clarivate Plc's Q1 2023 performance showcased stable revenue, strong margins, and strategic financial initiatives despite challenges in net income and organic growth cadence.
The company's strengths lie in market engagement, AI innovation, maintained outlook, and effective pricing strategies, positioning it for continued growth.
Challenges include earnings volatility, execution hurdles in growth projections, and longer-term segment revenue impacts, necessitating strategic planning and operational focus.
Opportunities in AI applications, cash flow utilization, revenue drivers, and segment progress offer avenues for revenue diversification, growth investments, and market expansion.

Clarivate Plc faces revenue challenges but drives growth through innovation

Clarivate Plc's Q2 performance saw challenges in key segments impacting revenue and outlook, despite operational improvements and strategic initiatives.
While facing hurdles in patent annuities and commercialization subsegment growth, the company focuses on sustainability, product innovations, and customer-centric strategies for future growth.
Detailed financial results and revised guidance reflect the company's proactive approach to address challenges and capitalize on opportunities for sustainable growth.
With a pivot around three segments and emphasis on higher-touch sales, Clarivate aims to navigate challenges, leverage opportunities, and drive revenue growth in the evolving market landscape.

Clarivate Plc reports Q3 growth, tackles challenges, eyes tech acquisitions

Clarivate Plc's Q3 performance showed growth in key segments despite challenges in IP and LS&H businesses.
Opportunities lie in technology acquisitions, analytic platforms, and direct sales to pharma companies.
Management remains optimistic about quarterly results and progress, focusing on enhancing growth strategies.

Clarivate Plc reports solid Q4 performance amidst sector challenges

Clarivate Plc's Q4 2023 performance reflects progress in key segments and a strategic focus on organic growth and operational efficiencies.
While facing challenges in the A&G segment and market conservatism, the company is leveraging strengths in Life Sciences investments and pricing strategies.
Opportunities lie in growth acceleration through new offerings, improved organic growth, and renewed optimism in the life sciences sector.

Clarivate Plc reports Q1 revenue growth, eyes segment expansion

Clarivate Plc's Q1 performance showed promising organic revenue growth and steady renewal rates, with a focus on future investments for growth.
While facing financial challenges and neutral market conditions, the company sees opportunities in segment growth and real-world data solutions.
Overall, Clarivate remains on track with full-year guidance, aiming for 1% organic growth and focusing on driving subscription business growth.

Clarivate Plc reports mixed Q2 results, focuses on growth strategies

Clarivate Plc reported mixed financial results in Q2 2024, with slight revenue growth but challenges in certain segments.
Management emphasized resilience in adjusted EPS and operating cash flow, focusing on growth plans and operational improvements.
Analysts raised concerns about project delays and segment performance, but opportunities in product innovation and revenue growth were highlighted.
The company aims to drive subscription revenue growth through upcoming product releases and investment in business.

Clarivate Plc faces revenue decline in Q3 but focuses on growth strategies

Clarivate Plc's Q3 2024 earnings call highlighted challenges in revenue decline and net loss, with a focus on repositioning and value creation. The company is implementing a Value Creation Plan to optimize its business model and drive sustainable growth. Opportunities exist in improving sales execution, product innovation, and aligning the portfolio for enhanced profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clarivate Plc engages in the provision of global information, analytics, and workflow solutions. It operates through the following segments: Academia and Government (A&G), Intellectual Property (IP), and Life Sciences and Healthcare (LS&H). The A&G segment involves the provision of research and analytics, content aggregation, and workflow software solutions using artificial intelligence. The IP segment includes the maintenance, intelligence, and management solutions. The LS&H focuses on solutions for research and development, regulatory and safety, and commercialization. The company was founded in 1864 and is headquartered in London, the United Kingdom.

Developed in partnership with the research community to implement high-quality AI tools responsibly LONDON , Sept. 4, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the Web of Science™ Research Assistant.

Clarivate Launches Generative AI-Powered Web of Science Research Assistant

LONDON , Aug. 20, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, has appointed Melanie Margolin to the expanded role of Chief Administrative and Legal Officer. She joined the company as Executive Vice President and Chief Legal Officer in September 2023.

Clarivate Names Melanie Margolin as Chief Administrative and Legal Officer

A buy rating is recommended for Clarivate due to the expected organic growth improvement. Recent earnings showed a revenue decline, but organic growth showed a positive recovery, particularly in the A&G and IP segments. Valuation is cheap at 6.5x forward PE, with potential for multiple expansions as growth accelerates.

Clarivate: Attractive Upside Even With Conservative Assumptions

LONDON , Aug. 7, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Jonathan Collins, Executive Vice President and Chief Financial Officer, will present at the Oppenheimer 27th Annual Technology, Internet & Communications Virtual Conference, on Monday, August 12, 2024 at 2:55 pm Eastern Time. The live webcast can be accessed at https://wsw.com/webcast/oppenheimer37/clvt/2805750 and will be available for replay.

Clarivate to Present at the Oppenheimer 27th Annual Technology, Internet & Communications Virtual Conference on August 12

Clarivate Plc (NYSE:CLVT ) Q2 2024 Earnings Conference Call August 6, 2024 9:00 AM ET Company Participants Mark Donohue - Vice President of Investor Relations Andrew Snyder - Chairman of the Board Jonathan Gear - Chief Executive Officer, Matti Shem Tov - Jonathan Collins - Chief Financial Officer Conference Call Participants Toni Kaplan - Morgan Stanley Manav Patnaik - Barclays Surinder Thind - Jefferies Shlomo Rosenbaum - Stifel Wahid Amin - Bank of America Owen Lau - Oppenheimer Andrew Nicholas - William Blair Ashish Sabadra - RBC Capital Markets George Tong - Goldman Sachs Operator Good morning. Thank you for attending the Clarivate Q2 2024 Earnings Conference Call.

Clarivate Plc (CLVT) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Clarivate (CLVT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Clarivate (CLVT) Q2 Earnings: A Look at Key Metrics

Clarivate PLC (CLVT) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.21 per share a year ago.

Clarivate PLC (CLVT) Surpasses Q2 Earnings Estimates

Chief Executive Jonathan Gear to Step Down as CEO and Member of the Board LONDON , Aug. 6, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced that the Board has appointed Matti Shem Tov, former CEO of ProQuest, as the Company's next CEO, effective August 9, 2024. Mr. Shem Tov will also join the Company's Board of Directors.

Clarivate Appoints Former ProQuest CEO Matti Shem Tov as the Company's Next CEO

— Reaffirms 2024 Outlook — LONDON , Aug. 6, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the second quarter ended June 30, 2024. Second  Quarter 2024 Financial Highlights Revenues of $650.3 million decreased 2.8% Organic revenues decreased 0.6%, as an increase in subscription revenues of 0.7% was offset by a decrease in re-occurring revenues of 0.7% and transactional and other revenues of 4.1% Net loss of $304.3 million; Net loss per diluted share of $0.46 Adjusted net income(1) of $142.2 million decreased 6.6%; Adjusted diluted EPS(1) of $0.20 decreased 4.8% or $0.01 Adjusted EBITDA(1) of $274.4 million decreased 3.7%; Adjusted EBITDA margin(1) of 42.2% decreased 40 basis points primarily due to lower revenues Net cash provided by operating activities of $126.2 million decreased $36.2 million; Free cash flow(1) of $60.3 million decreased $44.5 million primarily due to the timing of working capital Six Months Ended June 30, 2024 Financial Highlights Revenues of $1,271.5 million decreased 2.0% Organic revenues decreased 1.1% as an increase in subscription revenues of 1.5% was offset by a decline in re-occurring revenues of 2.9% and transactional and other revenues of 7.3% Net loss of $379.3 million; Net loss per diluted share of $0.61 Adjusted net income(1) of $245.7 million decreased 13.2%; Adjusted diluted EPS(1) of $0.34 decreased 12.8% or $0.05 Adjusted EBITDA(1) of $510.7 million decreased 5.0%; Adjusted EBITDA margin(1) of 40.2% decreased 120 basis points primarily due to lower revenues Net cash provided by operating activities decreased $87.5 million to $302.4 million; Free cash flow(1) decreased $100.9 million to $172.1 million primarily due to lower operating income and increased capital expenditures "We continue to invest in innovation and make progress on our strategy of returning to growth.

Clarivate Reports Second Quarter 2024 Results

Empowering biopharma with enhanced safety insights to anticipate risks and unlock new competitive advantages LONDON , July 30, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the launch of the new OFF-X™ platform. The enhanced solution offers a seamless user experience and unique translational insights.

Clarivate Introduces New OFF-X ™ Platform for Preclinical and Clinical Safety Intelligence

Valeria Alberola to Succeed as Audit Committee Chair LONDON , July 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Richard Roedel will retire from the Board of Directors (the "Board") for health reasons, effective December 31, 2024. The Board expects Valeria Alberola, a member of the Board since May 2021, and a member of its Audit and Finance Committees, to succeed Mr.

Clarivate Director Richard Roedel to Retire from Board of Directors

Clarivate (CLVT) partners with OhioLINK and SearchOhio to integrate their INN-Reach platforms to develop a unified library solution for the state of Ohio.

Clarivate (CLVT) to Develop Unified Library Solution for Ohio

Delivering integrated, AI-enabled solutions specifically designed for patent preparation and prosecution LONDON , July 22, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it has acquired Rowan TELS Corp. through a subsidiary. Rowan TELS Corp. is the provider of Rowan Patents – an integrated patent drafting and prosecution solution specially designed for patent practitioners to establish and protect patents more effectively.

Clarivate Acquires Rowan TELS to Enhance Support for Patent Practitioners

Bringing together Ohio's public and academic libraries' platforms to enhance and streamline customer-centric library resource sharing LONDON , July 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a partnership with OhioLINK, Ohio's academic library consortium, and SearchOhio, a consortium of Ohio public libraries, to develop a new library resource sharing consortial experience. Through this partnership Clarivate will unify OhioLINK and SearchOhio's resource sharing platforms to enhance library user experiences and services, improve operational efficiencies and build upon existing consortia collaboration.

Clarivate to Partner with OhioLINK and SearchOhio to Create a New Unified Library Experience Across the State of Ohio

Recognized for excellence in writing, news, mental health, financial/investment and economics categories LONDON , July 18, 2024 /PRNewswire/ -- BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has been honored with nine 2024 APEX Awards for Publication Excellence. This achievement underscores the BioWorld mission to deliver superior journalistic excellence, data-driven analysis and cutting-edge digital publishing.

BioWorld by Clarivate Celebrates Nine Wins at 2024 APEX Awards

LONDON , July 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the second quarter 2024 before the market opens on Tuesday, August 6, 2024. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com.

Clarivate to Report Second Quarter 2024 Results on August 6, 2024

Dynamic, interactive data visualizations reveal comprehensive view of the global research and innovation landscape LONDON , July 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released its annual G20 scorecard, compiled by expert analysts and data scientists at the Institute for Scientific Information (ISI)™. The annual G20 research and innovation scorecard examines the research and innovation capabilities of each G20 member through dynamic, interactive data visualizations.

Clarivate Annual G20 Scorecard Examines Global Research and Innovation Trends Across G20 Members

Consistency in infringement cases with an average of ten filings per month LONDON , July 10, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today launched the report One year later in the UPC: First insights from Darts-ip™ , which analyzes litigation data from the Unitary Patent Court's (UPC) inaugural year. The analysis sheds light on the future direction of the UPC and its continued role alongside the European national courts and other major global patent jurisdictions.

Clarivate Reveals First Year of Unitary Patent Court Litigation Activity

Clarivate NYSE: CLVT may not be the cheapest AI stock worth buying, but it is inexpensive and set up to rebound strongly over the next few quarters. Trading at a mere 7.5x its earnings outlook for 2025, it is a super-deep value compared to leading AI plays, and the estimates for earnings growth underestimate the company's potential.

Clarivate: The Cheapest AI Stock Worth Buying?

New report highlights challenges and opportunities in resilient MedTech industry LONDON , July 2, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the release of the MedTech Trends to Watch 2024 report, the second installment in a two-part series offering a predictive analysis of emerging trends shaping the MedTech industry. Highlighting both challenges—such as economic uncertainty, regulatory shifts and fragile supply chains—and opportunities such as the rise of ambulatory surgical centers and AI in MedTech, the report provides a comprehensive outlook on industry trajectory.

Clarivate Identifies Six Breakthrough MedTech Trends in 2024 Set to Unlock New Industry Opportunities

LONDON , June 27, 2024 /PRNewswire/ --  Clarivate Plc  (NYSE:CLVT), a leading global provider of transformative intelligence, today released a Global Research Report from the Institute for Scientific Information (ISI)™. The report integrates and interprets multiple data sources from across Clarivate™ portfolios to highlight the academic and societal benefits of the rapidly evolving landscape of digital health.

Clarivate Report Demonstrates Societal Impact of Digital Health Research and Innovation Growth

Guidewire Software

Jones Lang LaSalle

Pinterest

Tenet Healthcare

Goldman Sachs NYSE: GS released a list of their top 50 stocks based on expected AI-driven earnings leverage. The firm ranked companies across sectors according to forecasted productivity gains linked to AI-powered automation.

Top 5 Stocks to Watch for AI-Driven Gains That Aren't NVIDIA

Enabling users to save time and reduce risks in the IP filing and prosecution process LONDON , June 24, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today launched the IP Collaboration Hub™ at the 2024 Clarivate Ignite conference held in San Diego, U.S. The new solution integrates with Clarivate IP management systems (IPMS) to provide a central hub for collaborating with local agents worldwide. The IP Collaboration Hub enables users to save time and reduce risks in the IP filing and prosecution process by providing a portal for instructors and local agents to collaborate and exchange information, while automatically docketing everything in the IPMS.

Clarivate Launches IP Collaboration Hub

Adds Emerging Sources Citation Index™ for a simplified and unified category view LONDON , June 20, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the 2024 update to the Journal Citation Reports™ (JCR™). The reports provide an essential and comprehensive resource of high-quality journals, ranked by field to enable academic institutions, researchers and publishers to gauge the significance of journals in the global research landscape.

Clarivate Reveals World's Leading and Trusted Journals with the 2024 Journal Citation Reports

Emerging standouts set to transform drug discovery and development, revolutionize cancer treatment, and capture big pharma interest highlighted in third annual report LONDON , June 19, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its annual Companies to Watch report, highlighting seven innovative companies revolutionizing drug discovery and development. These companies are advancing antibody-drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects.

News for Clarivate Plc Stock (CLVT)